Exploration of the Combination of PLK1 Inhibition with Immunotherapy in Cancer Treatment
Background. PLK1 overexpression is oncogenic and is associated with poor prognosis in various cancers. However, the current PLK1 inhibitors have achieved limited clinical successes. On the other hand, although immunotherapies are demonstrating efficacy in treating many refractory cancers, a substant...
Main Authors: | Mengyuan Li, Zhixian Liu, Xiaosheng Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Journal of Oncology |
Online Access: | http://dx.doi.org/10.1155/2018/3979527 |
Similar Items
-
PLK1, A Potential Target for Cancer Therapy
by: Zhixian Liu, et al.
Published: (2017-02-01) -
Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
by: Jieqiong Wang, et al.
Published: (2016-05-01) -
Inhibition of PLK1 by p53 and by PLK1-targeted drugs
by: Ahmadi, Maryam
Published: (2018) -
Effects of MicroRNA modulation of PLK1 in Breast Cancer in combination with PLK1 inhibitor NMS-P937
by: Zalles, Nicole
Published: (2019) -
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
by: Zehang Jiang, et al.
Published: (2018-10-01)